Spyryx reports positive Ph I safety data for SPX-101

In February, Spyryx Biosciences Inc. (Durham, N.C.) reported that single and multiple ascending doses of inhaled SPX-101 for 14 days were well tolerated and led to no dose-limiting toxicities (DLTs) in a Phase I trial in 64 evaluable healthy volunteers. The placebo-controlled, Canadian trial evaluated safety and pharmacokinetics of the cystic fibrosis (CF) candidate.

SPX-101 is a peptide derived from BPI fold containing family A member 1 (BPIFA1; SPLUNC1; PLUNC; LUNX) that prevents activation of epithelial sodium channel (ENaC). The product uses an experimental version of the eFlow Nebulizer System from Pari GmbH (Starnberg, Germany)...